At least three molecular sets have therefore been suggested for breast cancer outcomes: luminal (positive hormonal receptors - HR), triple negative (negative HR/ negative Her2), and Her2 overexpression phenotypes [2-4]. This evidence concerns the gene ERBB2 and breast cancer.